Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC

Clinical trial NCT05894889 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05894889
Sponsor: Peking University
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Stage IIIB(N2) Non-small Cell Lung Cancer Stage IIA Non-small Cell Lung Cancer Stage IIB Non-small Cell Lung Cancer Stage IIIA Non-small Cell Lung Cancer

Start date: 2024-01-30
Primary completion: 2027-08-01
Enrollment: 70

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.